GlaxoSmithKline has recalled 394,230 bottles of its DynaCirc CR hypertension drug from the U.S. market after the manufacturer, Novartis, reported inconsistent packaging practices. The generic drug is manufactured at a Novartis plant in Lincoln, Nebraska. Glaxo said in a statement that it has received no reports of adverse events nor any complaints of contamination or tablet mix-ups in batches of the drug, but decided on the recall as a precautionary measure. The London-based company said it does not known when the Novartis facility will resume operations. Novartis said last month it had temporarily closed the plant to accelerate improvements at the site.
